Why the study?
Does discontinuation of TPO-RA therapy result in sustained platelet response in adult patients with persistent or chronic ITP and a documented complete response?
Does discontinuation of TPO-RA therapy result in sustained platelet response in adult patients with persistent or chronic ITP and a documented complete response?
Answers are grounded in this paper and cite their sources.
This editorial highlights evidence that TPO-RA therapy can potentially be discontinued in ITP patients who achieve a complete response, maintaining sustained platelet levels.
In this issue of Blood, Guillet et al report high rates of sustained platelet response following discontinuation of thrombopoietin receptor agonist (TPO-RA) therapy in adult patients with persistent or chronic immune thrombocytopenia (ITP) and a documented complete response (platelet count > 100 × 10 9 /L). 1Second-line treatment options for ITP include rituximab, splenectomy, and TPO-RAs.In the absence of clinical trials directly comparing these strategies, the choice of treatment is guided by patient values and preferences.Patients who value avoidance of surgery and/or immunosuppression and do not mind taking a regular medication can be considered for TPO-RA therapy.
No takes yet. Share an insight, caveat, or question.
Sanfilippo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: